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Chronic myelogenous leukemia (CML) is char-acterized by the increased and unregulated growth of predominantly myeloid cells in the 
bone marrow and the accumulation of these cells in the 
blood. This myeloproliferative disease is associated with 
a characteristic chromosomal translocation called the 
Philadelphia chromosome.1 In this translocation, parts 
of two chromosomes (9th and 22nd) switch places. As 
a result, part of the BCR gene from chromosome 22 
is fused with the ABL gene on chromosome 9.1 This 
abnormal “fusion” gene generates a protein of p210 kDa 
or sometimes p185 kDa weight and also known as ty-
rosine kinase.1 The bcr-abl transcript is continuously 
active and does not require activation by other cellular 
messaging proteins.1 In turn, bcr-abl activates a cascade 
of proteins that control the cell cycle, speeding up cell 
division.1 
The annual incidence of CML is 1-2 per 100 000 
people in Western countries.1 Its incidence is not well 
known in India. It occurs slightly more in men than 
women and the etiology of CML is not well known. 
CML is often divided into three phases and in the 
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BACKGROUND: chronic myeloid leukemia (cml) is a myeloproliferative disorder with a unique genetic rear-
rangement, the philadelphia chromosome. high reactive oxygen species (ros) levels favor oxidative stress, 
which could play a vital role in normal processes and various pathophysiologies including neoplasm. biomarkers 
of oxidative stress are measured as products of oxidized proteins and lipids. plasma levels of protein carbonyl 
(pc), thiobarbituric acid reactive substances (tbars) and total lipid hydroperoxide (looh) were used as bio-
markers of oxidative stress in the past. the aim of this study was to evaluate the products of protein oxidation 
and lipid peroxidation in plasma as biomarkers of oxidative stress in cml patients. 
PATIENTS AND METHODS: the study included 40 cml patients and 20 age- and sex-matched healthy volun-
teers. of 40 cml patients, 28 were in chronic phase (cml-cp) and 12 in accelerated phase (cml-ap). plasma 
levels of pc, tbars and looh as biomarkers of oxidative stress were evaluated by spectrophotometric methods. 
RESULTS: there were significant differences (p<.05) in plasma levels of pc, tbars and looh in cml, cml-cp 
and cml-ap patients as compared to controls. 
CONCLUSION: pc, tbars and looh might reflect oxidative stress in cml patients and might be used as 
biomarkers in such patients. 
absence of intervention, CML typically begins in the 
chronic phase, and over the course of several years pro-
gresses to an accelerated phase and ultimately to a blast 
crisis. Blast crisis is the terminal phase of CML and 
clinically behaves like an acute leukemia. 
Historically, CML has been treated with busulfan, 
hydroxyurea, interferon and bone marrow transplanta-
tion, although targeted therapies such as tyrosine kinase 
inhibitor (imatinib mesylate) introduced at the begin-
ning of the 21st century have radically changed the 
management of CML.1 
The oxidative stress can be defined as an imbalance 
between the production of reactive oxygen species 
(ROS) and a biological system’s ability to readily de-
toxify the reactive intermediates or easily repair the re-
sulting damage.2 These ROS can be generated within 
the cell not only by external sources of radiation such 
as x-ray or atomic bombing, but also within the body 
as a consequence of normal metabolic processes, which 
include drugs, electron transport chain and chemicals 
including toxins and dyes collectively termed as xe-
nobiotics.3 ROS are responsible for DNA, lipid and 
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protein damage and play an important role in the de-
velopment and progression of many human diseases 
including cancer.4-7 
Thus, there is a need for biomarkers to quantify as 
the intensity of oxidative stress. Direct measurements 
of ROS are not reliable due to the very short half-life of 
ROS and none of the techniques is sensitive for quan-
tification of ROS.8 The indirect methods for quantifi-
cation of ROS include measurement of damage prod-
ucts of protein carbonylation and lipid peroxidation.8 
Protein carbonylation was measured as protein carbon-
yl (PC) is a product of irreversible non-enzymatic oxi-
dation of protein whereas lipid peroxidation is evalu-
ated in term of thiobarbituric acid reactive substances 
(TBARS) and total lipid hydroperoxides (LOOH).8,9 
Oxidative stress is now recognized to be a prominent 
feature of many acute and chronic diseases, and even 
cancer and leukemias.4-13 The levels of these param-
eters have been shown to have value as indicators or 
biomarkers for oxidative stress and disease progression 
in a number of pathophysiologies.4-13 Carbonylation of 
protein often leads to a loss of protein function, which 
is considered a widespread marker of severe oxidative 
stress, damage and disease-derived protein dysfunction 
in various pathophysiologies.8,14 Increased level of lipid 
peroxidation products were found in plasma of patients 
with gynecological malignancies, breast cancer, squa-
mous cell carcinoma, colon cancer and various types 
of leukemia.6,9,15-19 We therefore, prospectively studied 
the products of protein carbonylation and lipid per-
oxidation in plasma as biomarkers of oxidative stress in 
chronic myeloid leukemia patients. 
PATIENTS AND METHODS 
Forty patients were diagnosed as having chronic my-
eloid leukemia on the basis of standard clinico-hema-
tological and cytogenetic criteria. Twenty age- and 
sex-matched healthy subjects were included in this 
prospective study. Of 40 CML patients, 28 were in 
chronic phase (CML-CP) and 12 in accelerated phase 
(CML-AP). The mean age of CML patients was 35.40 
(11.19) years, the median age 33 years and the range 
20-60 years. The mean age of healthy volunteers was 
31.70 (10.53) years, the median age 34 years and the 
range 18-55 years. Patients were given hydroxyurea or 
imatinib mesylate and the dose was adjusted on each 
follow-up to maintain total leukocyte counts between 
5000/mm3 and 10000 mm3. There were no nutritional 
or supportive antioxidant treatment given to patients 
and no control subjects have taken any nutritional an-
tioxidant as well. 
Informed consent was obtained from all the indi-
viduals included in the study. The present investigations 
were approved by the institutional ethical committees 
for biomedical research. At the time of blood collec-
tion, there was no evidence of tissues injuries, infection 
or any inflammatory manifestation in the patients or 
controls. Blood samples were taken from patients and 
control following an overnight fasting period into K2 
EDTA vials to avoid the probable influence of nutri-
tional factors on the ROS level. 
The plasma was separated by centrifugation at 3000 
rpm per 15 minutes. Plasma PC content was measured 
by spectrophotometric detection of protein hydrazone, 
which is formed by the reaction between 2,4-dinitro-
phenyl hydrazine (DNPH) and PC.20 The results were 
expressed as n moles of PC content per milligram of pro-
tein by using wavelength 370 nm with molar extinction 
coefficient ε370=22 000 M-1cm-1. The protein content was 
determined by the Lowry method using bovine serum 
albumin as a standard.21 The TBARS in the plasma was 
evaluated by slightly modified spectrophotometric meth-
od based on the reaction between MDA and thiobarbi-
turic Acid (TBA).20 Absorbance was measured by spec-
trophotometerically at a wavelength 532 nm with molar 
extinction coefficient ε532=1.56×105 M-1cm-1.22 Total 
hydroperoxide (LOOH) level in plasma was estimated 
using the ferrous oxidation in xylenol orange Fox-2 as-
say by spectrophotometerically.23 Plasma level of TBARS 
and LOOH were expressed as n mole MDA/mL and 
mM/mL respectively. 
The findings were expressed as the mean and stan-
dard deviation. The differences were compared with the 
use of unpaired t test. A value of P<.05 was considered 
statistically significant. 
12
10
8
6
4
2
0
            Control                            CmL                           CmL-CP                        CmL-AP
Pl
as
m
a 
PC
 (n
 m
ol
e/
m
g)
Figure 1. Plasma protein carbonyl (PC) levels in CmL patients and controls. (CP: chronic 
phase, AP: accelerated phase) 
*mean values are expressed as ±SD. Statistically significant (P≤.05) in comparison to control.
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RESULTS 
Present study was conducted to assess the PC, TBARS 
and LOOH as biomarkers of oxidative stress in chronic 
myeloid leukemia patients. Plasma protein carbon-
ylation or oxidation was assessed as PC, which was 
significantly (P<.05) higher in CML patients as com-
pared with controls (Figure 1). The mean (SD) plasma 
PC levels in CML, CML-CP, CML-AP patients and 
controls were 3.94 (2.83), 2.72 (1.87), 6.78 (2.69) and 
1.88 (1.43) n mole/mg respectively. Plasma lipid per-
oxidation levels were measured in term of TBARS and 
LOOH and were found significantly increased (P<.05) 
in CML patients as compared with controls (Figures 2, 
3). The mean plasma levels TBARS in CML, CML-CP, 
CML-AP patients and controls were 3.91 (1.64), 3.47 
(1.05), 4.94 (2.28) and 2.47 (0.80) n mole MDA/mL, 
respectively. We found significance variation between 
levels of mean plasma TBARS in control and clinical 
phases of CML. The mean plasma level of LOOH in 
CML, CML-CP and CML-AP were 0.64 (0.24), 0.55 
(0.21) and 0.85 (0.15) mM/mL whereas in control was 
0.41 (0.16) mM/mL, respectively. We also found sig-
nificantly different levels of mean plasma LOOH be-
tween clinical phases of CML and control. 
DISCUSSION 
Generally speaking, oxidative stress is defined as an im-
balance between the level of ROS and the antioxidant 
defense system, in favor of the former.2 Oxidative stress 
plays a variety of roles in normal biological processes, 
pathogenic processes, or pharmacological responses to 
a therapeutic intervention.4-19 Biomarkers are defined 
as characteristics that can be autonomously measured 
and analyzed as indices of oxidative stress.8 Various in 
vitro markers of oxidative stress are available, including 
ROS themselves, but most have imperfect value in vivo 
because they lack sensitivity, specificity, or require inva-
sive methods.8 Although some ROS have been directly 
detected in vitro by chemiluminescence or by electron 
spin resonance with or without spin-trapping reagents, 
these direct detection methods are not yet appropriate 
for clinical research because of the instability of ROS 
and the need for costly equipment.8 Furthermore, ROS 
are generally extremely reactive and have a half-life too 
short to measure in cells, tissues, or body fluids.8 
Molecular products or metabolic products formed 
from the reaction between ROS and bio-molecules 
are generally considered more stable than ROS them-
selves.8 These products are too stable to evaluate more 
easily than direct evaluation of ROS.8 In previous stud-
ies, various metabolic products have been described as 
biomarkers for oxidative stress in a numbers of patholo-
gies.8 Most commonly metabolic products include prod-
ucts of oxidation of proteins and lipids. PC is an irre-
versible product of protein oxidation whereas TBARS 
and LOOH is the product of lipid oxidation.8,9,14 A 
study on breast cancer provided evidence that protein 
oxidation might be associated with cancer risk.24 A sig-
nificant level of plasma PC was observed in patients 
with Hodgkin lymphoma, colon cancer, bladder cancer 
and lung cancer and in children with various malignan-
cies.16,25-27 TBARS and LOOH are well-defined lipid 
peroxidation or oxidation end products. The TBARS 
is considered to be mutagenic and carcinogenic.4 It can 
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Figure 2. Plasma thiobarbituric acid reactive substances (TBArS) levels in CmL patients 
and controls. (CP: chronic phase, AP: accelerated phase)
*mean values are expressed as ±SD. Statistically significant (P≤.05) in comparison to control.
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*mean values are expressed as ±SD. Statistically significant (P≤.05) in comparison to control.
Figure 3. Plasma lipid hydroperoxide (LOOH) levels in CmL patients and controls. (CP: 
chronic phase, AP: accelerated phase)
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also modulate the expression of genes related to initiation 
and progression of cancer.4 Increased level of TBARS 
was found in patients with breast cancer, gynecological 
malignancies, squamous cell carcinoma, colon cancer, 
cervical cancer and various types of leukemia.6,9,13,15-19 A 
significant increased level of LOOH was found in pa-
tients with obstructive jaundice and colon cancer.16,28 
Elevated level of PC, TBARS and LOOH sup-
port the hypothesis that high ROS generation occurs 
in neoplastic or cancer cells. It was demonstrated that 
bcr-abl fusion protein is associated with increased lev-
els of ROS in hematopoietic cell lines compared with 
their non-transformed parental cell lines.29 High ROS 
and increased activity of tyrosine kinase protein play an 
important physiological role in signal transduction and 
induced proliferative pathway in the cell.29 A current re-
port states that bcr-abl kinase stimulates ROS, which 
causes oxidative DNA damage, resulting in mutations 
in the kinase domain.30 It was suggested that ROS 
might play a major role in resistance to given therapy, 
which could contribute to progression of CML.30 
Our suggestion for the mechanism of higher PC, 
TBARS and LOOH levels in plasma is that mature 
and immature myeloid cells as well as other unknown 
factors are the major source of ROS, which leads to 
oxidative stress in the cells, if antioxidant system is 
not powerful. There may be comparability between 
numbers of mature/immature myeloid cells and bcr-
abl fusion protein with disease progression. The bcr-
abl fusion protein has also been linked with genomic 
instability, progression of the disease, increased ROS 
production and additional karyotypic abnormalities.30 
These circumstances build an intracellular milieu more 
favorable for macromolecules damage, mutations and 
disease progression. Hence, it can be implied that in 
CML, plasma PC, TBARS and LOOH levels may pre-
cisely reflect the degree of oxidative stress with disease 
phenotype. We suggest that plasma PC, TBARS and 
LOOH may serve as biomarkers for oxidative stress in 
patients with CML. A highly structured study with a 
larger sample size is required to establish the precise 
role of oxidative stress in pathobiology of CML. 
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